Valsartan And Hydrochlorothiazide
Product Images NDC 50090-1763

8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-1763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500901762)

Label Image (Lbl500901762)
Packaging label for Valsartan and Hydrochlorothiazide tablets, 320 mg/25 mg strength, by A-S Medication Solutions. The label shows the product number 6488-0 and includes storage instructions to store at 68 to 77 degrees Fahrenheit, protected from moisture and heat. The package contains 90 tablets.*
FDA Label Image

Lbl500901763

Lbl500901763
Packaging label for Valsartan and Hydrochlorothiazide 160 mg/25 mg tablets by A-S Medication Solutions. The label indicates a bottle containing 90 tablets with storage instructions to keep between 68 to 77 degrees Fahrenheit and protect from moisture and heat. The NDC is 50090-1763-0.*
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
A line graph titled 'Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8' showing percentage of patients with systolic blood pressure under 140 mmHg versus baseline systolic blood pressure (mmHg). It compares four groups: Valsartan and Hydrochlorothiazide 320 mg/25 mg (highest probability), Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo (lowest probability), with probabilities decreasing as baseline systolic blood pressure increases.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)
A line graph illustrating the probability of achieving diastolic blood pressure less than 90 mmHg at various baseline diastolic blood pressure levels. It compares four treatments: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, showing their effectiveness across baseline DBP values from 90 to 110 mmHg.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)
A line graph showing the probability of achieving systolic blood pressure (SBP) less than 130 mmHg at Week 8, related to baseline SBP values. It compares Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo groups. The vertical axis represents the percentage achieving SBP <130 mmHg, and the horizontal axis represents baseline SBP in mmHg.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)
A line graph illustrating the probability of achieving diastolic blood pressure (DBP) below 80 mmHg at week 8. The x-axis represents baseline DBP in mmHg (90 to 110), and the y-axis shows the percentage achieving DBP <80 mmHg. Four lines compare Valsartan and Hydrochlorothiazide 320 mg / 25 mg combination, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo.*
FDA Label Image

Chemical Structure1 (Valhyctz Str1)

Chemical Structure1 (Valhyctz Str1)
Chemical structure of valsartan, one of the active ingredients in the combination drug Valsartan and Hydrochlorothiazide by A-S Medication Solutions.*
FDA Label Image

Chemical Structure 2 (Valhyctz Str2)

Chemical Structure 2 (Valhyctz Str2)
Chemical structure diagram of the active ingredient, clearly illustrating a chlorinated benzene ring with attached sulfonamide and heterocyclic groups, associated with the product Valsartan and Hydrochlorothiazide by A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.